Prosecution Insights
Last updated: August 06, 2026
Application No. 18/245,694

ANTI-4-1BB-ANTI-PD-L1 BISPECIFIC ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

Final Rejection §112
Filed
Mar 16, 2023
Priority
Sep 17, 2020 — CN 202010983606.7 +1 more
Examiner
AEDER, SEAN E
Art Unit
1642
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BIOTHEUS INC.
OA Round
2 (Final)
57%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
808 granted / 1421 resolved
-3.1% vs TC avg
Strong +20% interview lift
Without
With
+19.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
64 currently pending
Career history
1492
Total Applications
across all art units

Statute-Specific Performance

§101
14.8%
-25.2% vs TC avg
§103
26.2%
-13.8% vs TC avg
§102
17.3%
-22.7% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1421 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action The Amendments and Remarks filed 6/17/26 in response to the Office Action of 3/19/26 are acknowledged and have been entered. Claims 32-40 have been added by Applicant. Claims 1-10, 15, 16, 18, 20, and 32-40 are pending. Claims 1-10, 15, 16, and 20 have been amended by Applicant. Claims 1-10, 15, 16, 18, 20, and 32-40 are currently under examination. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The following Office Action contains NEW GROUNDS of rejections Necessitated by Amendments. Rejections Withdrawn All previous rejections are withdrawn. New Rejections Necessitated by Amendments Claim Rejections - 35 USC § 112 Claims 5-10 and 34-39 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 5-10 and 35-39 are rejected because claims 5-7 and 9 each recite “the heavy chain constant region of IgG”. There is insufficient antecedent basis for “the heavy chain constant region of IgG” in the claims. Claim 34 recites “The bispecific antibody according to claim 5, wherein the linker has….” Claim 5 recites bispecific antibodies with two linkers. It is unclear which linker of a bispecific antibody of claim 5 is “the” linker. There is insufficient antecedent basis for “the linker” in claim 34. Allowable Subject Matter Claims 1-4, 15, 16, 18, 20, 32, 33, and 40 are allowed. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEAN E AEDER whose telephone number is (571)272-8787. The examiner can normally be reached M-F 9am-6pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571)270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SEAN E AEDER/Primary Examiner, Art Unit 1642
Read full office action

Prosecution Timeline

Mar 16, 2023
Application Filed
Mar 19, 2026
Non-Final Rejection mailed — §112
Jun 17, 2026
Response Filed
Jul 02, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12685734
N6-Methyladenosine Regulators in Uterine Fibroids
3y 9m to grant Granted Jul 21, 2026
Patent 12673107
USE OF THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF PATIENTS WITH TUMORS OF EPITHELIAL ORIGIN
4y 0m to grant Granted Jul 07, 2026
Patent 12669505
DETECTION OF DESMOGLEIN-2 IN CANCERS OF EPITHELIAL ORIGIN
4y 2m to grant Granted Jun 30, 2026
Patent 12667616
Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
9m to grant Granted Jun 30, 2026
Patent 12656350
METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING A SAGE1-RELATED CONDITION
4y 0m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
57%
Grant Probability
77%
With Interview (+19.9%)
3y 0m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1421 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month